This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Oral
T-DXd
ESMO 2024 | September 13-17, 2024
A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
A real-world study of the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (mBC) among racial and ethnic minorities and older populations in the United States: Trial in progress (TiP)
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
A retrospective study to investigate the prevalence and treatment outcomes of HER2-low unresectable/metastatic breast cancer in Taiwan — the RetroBC-HER2L-TW study
Oral
T-DXd
JBCS 2025 | July 10-12, 2025
AI-based analyses of trastuzumab deruxtecan-related interstitial lung disease/pneumonitis: TILD-A
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Baseline serum protein analysis of patients with interstitial lung disease/pneumonitis (ILD) in 3 trastuzumab deruxtecan (T-DXd) trials: DESTINY-Breast01, DESTINY-Breast04, and DESTINY-Lung01
Poster
T-DXd
ESMO Breast 2025 | May 14-17, 2025
Chemotherapy outcomes in human epidermal growth factor receptor 2 (HER2)‑low, hormone receptor positive (HR+) metastatic breast cancer (mBC): Insights from the French multicenter ESME database
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Clinical characteristics of patients with HER2+ unresectable or metastatic breast cancer: HER2 REAL Asia cohort
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Concordance between the DESTINY-Breast04/06
VENTANA 4B5 HER2 IHC clinical trial assay
and other comparator assays for HER2-low
breast cancer: Overall results of a large-scale,
multicenter, global ring study
Mini-Oral
Dato-DXd
ESMO Asia 2024 | December 6-8, 2024
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with pre-treated inoperable/metastatic HR+/HER2– breast cancer: Results from TROPION-Breast01 China cohort
Mini-Oral
T-DXd
ESMO Breast 2025 | May 14-17, 2025
DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC)